Diabetic Nephropathies, Glomerulonephritis, IGA, Glomerulonephritis, Membranous, Hyperspectral Imaging, Nephrosis, Lipoid
Conditions
Brief summary
Morning urine samples of patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from November 2020 to January 2022 were collected. By scanning the morning urine samples of corresponding patients with microhyperspectral imager, machine learning and deep learning were used to classify microhyperspectral images, and the classification accuracy was greater than 85%. Thus, hyperspectral imaging technology could be used as a non-invasive diagnostic means to assist the diagnosis of glomerular diseases.
Interventions
Microscopic hyperspectral imaging system
Sponsors
Study design
Eligibility
Inclusion criteria
* Over 18 years old; * Patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, minimal change nephropathy confirmed by renal biopsy; * Had not received hormone and/or immunosuppressive therapy before renal biopsy; * Complete clinical data, all signed the Admission Certificate of Qianfoshan Hospital of Shandong Province, and agreed to use relevant medical information, biological specimen examination and examination results for scientific research.
Exclusion criteria
* There are factors causing secondary membranous nephropathy, such as immune diseases (systemic lupus erythematosus), tumors/infections (viral hepatitis), drugs or poisons, etc.; * Severe infection: fever, cough and expectoration, sore throat, abdominal pain, diarrhea, carbuncle and furuncle and other clinical manifestations of skin and soft tissue infection, blood routine white blood cell count beyond the normal range (10×109/L); * Severe cardiovascular disease: including chronic heart failure grade 3 or above and various arrhythmias; * Infectious diseases: active hepatitis, AIDS, syphilis, etc. ; * Tumor evidence: it has been found that there is a certain tumor or clinical manifestations, tumor markers, etc., suggesting the possibility of tumor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microhyperspectral image of urine specimen | 2023.4-2023.10 | Microhyperspectral images of urine samples from patients with four different glomerular diseases before treatment |